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Protein N-glycosylation is a widespread post-
translational modification. The first committed
step in this process is catalysed by dolichyl-
phosphate N-acetylglucosamine-phosphotrans-
ferase DPAGT1 (GPT/E.C. 2.7.8.15). Missense
DPAGT1 variants cause congenital myasthenic
syndrome and disorders of glycosylation. In addi-
tion, naturally-occurring bactericidal nucleoside
analogues such as tunicamycin are toxic to eu-
karyotes due to DPAGT1 inhibition, preventing their
clinical use. Our structures of DPAGT1 with the
substrate UDP-GlcNAc and tunicamycin reveal sub-
strate binding modes, suggest a mechanism of
catalysis, provide an understanding of how muta-
tions modulate activity (thus causing disease) and
allow design of non-toxic ‘‘lipid-altered’’ tunicamy-
cins. The structure-tuned activity of these ana-
logues against several bacterial targets allowed
the design of potent antibiotics for Mycobacterium
tuberculosis, enabling treatment in vitro, in cellulo
and in vivo, providing a promising new class of
antimicrobial drug.Cell 175, 1045–1058, Nove
This is an open access article undINTRODUCTION
N-glycosylation of asparagine residues is a common post-trans-
lational modification of eukaryotic proteins, required for protein
stability, processing, and function. Many diseases are associ-
ated with incorrect glycosylation (Freeze et al., 2012). This
process requires dolichol-PP-oligosaccharides that provide the
oligosaccharides that are transferred (Helenius and Aebi,
2004). The first step in dolichol-PP-oligosaccharide production
involves the ER integral membrane enzyme dolichyl-phosphate
alpha-N-acetyl-glucosaminyl-phosphotransferase (DPAGT1,
E.C. 2.7.8.15, also known as GlcNAc-1-P Transferase [GPT]). It
catalyzes the transfer of an N-acetyl-D-glucosamine-1-phos-
phoryl unit (GlcNAc-1-P) from UDP-N-acetyl glucosamine
(UDP-GlcNAc) onto dolichyl phosphate (Dol-P) (Figure 1A) (Hei-
fetz and Elbein, 1977; Lehrman, 1991). The product GlcNAc-PP-
Dol is anchored to the ER membrane by its dolichyl moiety and
then monosaccharide units are added sequentially to build the
N-glycan that is then transferred.
Mutations inDPAGT1 impair proteinN-glycosylation, leading to
at least two syndromes, depending on the extent of loss of activ-
ity. Congenital myasthenic syndrome (DPAGT1-CMS OMIM ref:
614750) is a neuromuscular transmission disorder characterized
by fatigableweaknessof proximalmuscles (Basiri et al., 2013;Be-
laya et al., 2012; Iqbal et al., 2013). Reduced endplate acetylcho-
line receptors (AChR) andabnormal synaptic structuremaybe thember 1, 2018 ª 2018 The Authors. Published by Elsevier Inc. 1045
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Structural Features of DPAGT1
(A) Cartoon of DPAGT1 reaction.
(B) Michaelis-Menten kinetics, non-titrated sub-
strate at 200 mM. Measurements were performed
with three biological and three technical repeats.
Data presented are means ± SD.
(C) Topology of DPAGT1; helices shown as cylin-
ders, strands as arrows and active site in magenta.
(D) Schematic of DPAGT1 structure. Views shown
looking along membrane plane and onto the cyto-
plasmic face; UDP-GlcNAc in magenta.
(E) Comparison of DPAGT1 (orange) and MraY
(PDB: 5CKR; purple) folds.
(F) CL9 domain in DPAGT1.
(G) CL9 strand (loop ‘‘E’’) and helix in MraY.result of incorrect glycosylation of AChR and other proteins.
Mutations in DPAGT1 also cause congenital disorder of glycosyl-
ation type Ij (CDG-Ij, OMIM ref: 608093) (Carrera et al., 2012; Sel-
cenet al., 2014;Wuet al., 2003;Wu¨rde et al., 2012), amore severe1046 Cell 175, 1045–1058, November 1, 2018multisystem syndrome that can cause
intellectual disability, epilepsy, micro-
cephaly, severe hypotonia and structural
brain anomalies.
Inhibition of polyisoprenyl-phosphate
N-acetylaminosugar-1-phosphoryl trans-
ferases (PNPTs) such as DPAGT1 and
the bacterial enzymeMraY, is lethally toxic
to many prokaryotic and eukaryotic organ-
isms. Streptomyces bacteria exploit this
toxicity by producing the PNPT inhibitor
tunicamycin, which blocks MraY, a critical
enzyme in biosynthesis of cell walls in
many bacterial pathogens (Figures S1A
and S1B) (Dini, 2005). Unfortunately, it
also inhibits eukaryotic PNPTs, such as
DPAGT1 (Heifetz et al., 1979) causing se-
vere toxicity in eukaryotic cells. However,
although bacterial (e.g., MraY) and human
(e.g., DPAGT1) PNPTs are similar, it
should be possible to design syntheti-
cally-altered tunicamycin analogues that
specifically inhibit bacterial proteins.
Here we present structures of human
DPAGT1 with and without ligands. The
protein production methods, structures,
assays and complexes are components
of a ‘‘target enabling package’’ developed
at the Structural Genomics Consortium
(released June 2017, http://www.thesgc.
org/tep/DPAGT1), which has already
been used by others (Yoo et al., 2018).
These structures, combined with muta-
genesis and activity analysis, reveal both
the mechanism of catalysis by DPAGT1
and the molecular basis of DPAGT1-
related diseases. To improve the effective-
ness of tunicamycin as a drug, wemodified its core scaffold, TUN, using a scalable, semi-
synthetic strategy that enabled selective lipid chain addition.
These analogues show nanomolar antimicrobial potency, abla-
ted inhibition of DPAGT1, much reduced toxicity, allowed
effective treatment of Mycobacterium tuberculosis (Mtb) in
mammals, providing leads for tuberculosis (TB) antibiotic
development.
RESULTS
DPAGT1 Activity and Architecture
To determine the structure of DPAGT1, we expressed both
full-length wild-type (WT) DPAGT1 and the missense mutant
Val264Gly in the baculovirus/insect cell system. The Val264Gly
mutation is a variant found in some CMS patients (Belaya
et al., 2012), which improved crystallization behavior compared
to WT. We tested the enzymatic activity of WT and Val264Gly
DPAGT1 to confirm that the protein was functional. Product
GlcNAc-PP-Dol was confirmed by mass spectrometry (Fig-
ure S1C). WT DPAGT1 has an apparent Km of 4.5 ± 0.8 mM
and a kcat of 0.21 ± 0.007min
-1 towards UDP-GlcNAc (Figure 1B,
STAR Methods); Dol-P displayed an apparent Km of 36.3 ±
7.2 mMand a kcat of 0.20± 0.012min
-1 (Figure 1B). The Val264Gly
mutant showed 2.5-fold higher activity (Figure S1D) and similar
thermostability to WT protein (Tm1/2 of 51.7 ± 0.2
C for WT
and 50.4 ± 0.3 C for mutant, Figure S1E, STAR Methods, Table
S1). Adding the product analogue GlcNAc-PP-Und (equimolar to
Dol-P and UDP-GlcNAc) reduced activity 3-fold, the addition of
the other product, UMP, had no effect (Figure S1F). Tunicamycin
fully inhibited at 1:1 molar ratio with DPAGT1 (Figure S1G). While
both substrates thermostabilized WT and mutant DPAGT1 by
3–7 C, tunicamycin thermostabilized both by more than 30 C
(Figure S1E). Interestingly, phosphatidylglycerol co-purified
with DPAGT1, even when not added to the purification, suggest-
ing a role for phosphatidylglycerol in the stability of DPAGT1
(Figures S1H and S1I).
The crystal structures of the WT DPAGT1 and Val264Gly
mutant were solved by X-ray crystallography using molecular
replacement with the bacterial homologue MraY (Chung et al.,
2013, PDB: 4J72, 19% identity) as an initial model (STAR
Methods). The apo WT- and Val264Gly-DPAGT1 proteins gave
structures to 3.6 A˚ and 3.2 A˚ resolution (Table S2). Complexes
with UDP-GlcNAc and tunicamycin gave data to 3.1 A˚ and
3.4 A˚ resolution, respectively (Figure 1, Figures S2A–S2E and
Table S2). In the crystals DPAGT1 is a dimer formed through a
crystallographic 2-fold axis (Figure S2F), with an 1850 A˚2 interac-
tion surface. The interface observed is similar to that seen in the
Yoo et al., 2018 structures, although in that case the crystals
show a dimer in the asymmetric unit. Interestingly, comparison
with the dimeric bacterial homologueMraY, showed that the sur-
face that forms the dimer interface differs between DPAGT1 and
MraY (Figure S2G) (Yoo et al., 2018). In solution, DPAGT1 exists
predominantly as a dimer, as shown by native mass spectrom-
etry, although the monomer was also detected (Figures S2H
and S2I). A Leu103Phe mutation introduced at the dimer inter-
face to disrupt this interaction gave unstable protein, suggesting
that DPAGT1 dimerization plays a role in stability. In the dimer
interface the sidechains of Cys106 are adjacent, but no intermo-
lecular disulfide bondwas observed in our electron density maps
(Figure S2J). To assess the presence of this potential disulfide,
DPAGT1 was purified without reducing agents and its mass
matched only monomer (STAR Methods). No covalent, disul-fide-bonded dimer was observed. We concluded that DPAGT1
exists predominantly as a non-covalent dimer in solution and
that dimerization is important for its stability.
The DPAGT1 structure (as reported here and by Yoo et al.,
2018) consists of 10 transmembrane helices (TMH1 to 10), with
both termini in the ER lumen (Figures 1C and 1D). Five loops con-
nect the TMHs on the cytoplasmic side of the membrane (CL1,
-3, -5, -7, and -9), which form the active site, 3 loops on the ER
side of the membrane (EL2, -4, -6) and one (EL8) embedded in
the membrane on the ER side. DPAGT1 has a similar overall
fold to MraY (Chung et al., 2013; Yoo et al., 2018) (Figure 1E).
A feature of the eukaryotic DPAGT1 PNPT family not found in
prokaryotic PNPTs is a 52-residue insertion between Arg306-
Cys358 in CL9, following TMH9. This motif adopts a mixed a/b
fold with an extended structure with 2 b-hairpins, a 3-stranded
b-sheet (Cb5-Cb7) and two amphipathic a-helices (CH2/CH3).
This CL9 domain (Figure 1F) forms part of the substrate recogni-
tion site in human DPAGT1 but not in bacterial MraY (Figure 1G).
The active site is on the cytoplasmic face of the membrane,
formed by the 4 cytoplasmic loops between the TMHs (Fig-
ure 2A). The long CL1 loop forms the ‘‘back wall’’; CL5 and
CL7 form the base and the ‘‘side walls’’ are formed by TMH3-
CL3-TMH4, TMH9b and the extended loop at the start of the
CL9 domain (Ile297-Pro305). The entrance to the catalytic site,
between TMH4 and TMH9b, is open and accessible from the
lipid bilayer via a 10 A˚ wide cleft. Within the membrane, adjacent
to the active site, there is a hydrophobic concave region (Fig-
ure 2B), created by a 60

bend in TMH9 midway through the
bilayer, which creates a groove in the DPAGT1 surface
(Figure 1D).
Binding Mode for UDP-GlcNAc and Metal Ion
The structure of the DPAGT1/UDP-GlcNAc complex reveals an
overall stabilization of the active site, due to movements of
CL1 and CL9, and the N terminus of TMH4 (Figure 2C), without
any global changes in conformation. The C-terminal end of
TMH9b and the following loop region (Phe286-Ile304) display
the largest conformational change with an induced fit around
the GlcNAc-PP (Figure 2C).
The uridyl moiety of UDP-GlcNAc lies in a narrow cleft at the
back of the active site formed by CL5 and CL7. The uracil ring
is sandwiched between Gly189 and Phe249 with additional
recognition conferred by hydrogen bonds between the Leu46
backbone amide, the Asn191 sidechain to the uracil carbonyls
(Figures 2D and 2E) and an extensive hydrogen bond network
involving two waters links the uracil ring to five residues (Figures
2D and 2E). Hydrogen-bonding of the ribosyl hydroxyls to the
Gln44 mainchain carbonyl and Glu56 sidechain carboxylate
complete the recognition of the uridyl nucleotide.
The pyrophosphate bridge is stabilized by interactions with
Arg301 and by the catalytic Mg2+ (Figure 2D). The Arg301 side-
chain coordinates one pair of a and b phosphate oxygen atoms,
whilst the Mg2+ ion is chelated by the second pair of a and b
phosphate oxygens. Each oxygen atom is thus singly coordi-
nated in an Arg-Mg2+-‘‘pyrophosphate pincer.’’ The octahedral
coordination of the Mg2+ ion is completed by the sidechains of
conserved residues Asn185 and Asp252, and 2water molecules.
Data from DPAGT1 co-crystallized with UDP-GlcNAc and Mn2+Cell 175, 1045–1058, November 1, 2018 1047
Figure 2. DPAGT1 Active Site
(A) The loops that form the active site; UDP-GlcNAc in magenta.
(B) Slicedmolecular surface showing occluded active site cleft and putative Dol-P recognition groove. Surface is coloured by electrostatic potential; UDP-GlcNAc
in magenta.
(C) Conformational changes with UDP-GlcNAc binding. Protein depicted in tube form with the tube thickness and colouring reflecting the rmsd in mainchain
atomic positions between the unbound and UDP-GlcNAc-bound structures.
(D) UDP-GlcNAc binding in active site. Omit Fo-Fc difference electron density shown for UDP-GlcNAc (green mesh, contoured at 3s) and 4 A˚ anomalous dif-
ference Fourier electron density (magenta mesh, contoured at 15s) from a dataset with MnCl2.
(E) Recognition of uridine moiety of UDP-GlcNAc.
(F) Schematic representation of interactions made by UDP-GlcNAc.
(G) Tunicamycin binding in active site.
(H) Schematic representation of interactions made by tunicamycin.gave a single anomalous difference peak at themetal ion binding
site, confirming the presence of a single Mg2+ ion in the active
site (Figure 2D). The position of the Mg2+ ion differs by 4 A˚
from that observed in MraY unliganded structure and the co-
ordination differs (Chung et al., 2013).
The GlcNAc moiety-binding site is formed by the CL9 domain
and the CL5 loop, although all the direct hydrogen bond interac-
tions are with the CL9 domain. The OH3 and OH4 hydroxyls of1048 Cell 175, 1045–1058, November 1, 2018GlcNAc form hydrogen bonds with the sidechain of His302 and
the mainchain amide of Arg303, respectively. The mainchain of
residues 300–303 and the sidechain of Arg303 define theGlcNAc
recognition pocket by specifically recognizing the N-acetyl
substituent, forming a wall to the sugar-recognition pocket
that appears intolerant of larger substituents, thereby ‘‘gating’’
substrate. This structure is absent in MraY, which has a much
smaller CL9 loop.
Figure 3. Proposed DPAGT1 Catalytic Mechanism
(A) Relative activity of active site mutant residues; (n=9).
(B) UDP-GlcNAc complex active site structure with Dol-P modelled based on
tunicamycin complex lipid chain position.
(C) Proposed DPAGT1 catalytic mechanism.
For all panels, data presented are means ± SD.Surprisingly, this structure does not support prior predictions
that the highly conserved ‘‘aspartate rich’’ D115Dxx(D/N/E)119
motif is directly involved in Mg2+ binding and/or catalysis (Lloyd
et al., 2004). This sequence is adjacent to the active site, but
these residues do not directly coordinate Mg2+ or substrate (Fig-
ure 2D). Instead, Asp115 is hydrogen-bonded to Lys125 and
Tyr256. Lys125 lies adjacent to the phosphates (Figure 2D) andhas been implicated in catalysis (Al-Dabbagh et al., 2008).
Asp116 forms hydrogen bonds to Ser57 and Thr253 and
N-caps TMH8, thus stabilizing residues that interact with the
UDP ribosyl moiety (Glu56) and the Mg2+ (Asp252). DPAGT1
with residues Asp115 and Asp116 mutated to Asn, Glu, or Ala
retained at least 10% of WT activity (Figure 3A), suggesting
they are not essential for catalysis. The third residue in this
motif, Asn119, makes no significant interactions. Thus, 2 of
the 3 conserved residues perform structural roles; none are
directly involved in Mg2+-binding or catalysis.
Comparison of the UDP-GlcNAc and Tunicamycin
Complexes
The structure of the complex between tunicamycin and DPAGT1
(thisworkandYooet al., 2018) suggests that inhibition is achieved
through partial mimicry of the Michaelis complex formed during
catalysis with acceptor phospholipid Dol-P and UDP-GlcNAc.
The uridyl and GlcNAcmoieties in tunicamycin and UDP-GlcNAc
occupy essentially identical sites (Figures 2G and 2H). In tunica-
mycin the pyrophosphate of UDP-GlcNAc is replaced by a galac-
tosaminylmoiety,whichdisplaces theMg2+ and interactswith the
sidechains of Arg301, Asp252, and Asn185.
Tunicamycin’s mimicry of Dol-P also gave critical insight into
the potential binding of co-substrate Dol-P. The lipid chain of tu-
nicamycin occupies the concave groove that runs along TMH5,
between helices TMH4 and TMH9a (see above). The sidechain
of Trp122 pivots around its Cb–Cg bond to lie over the lipid chain,
trapping it in a tunnel. The surface beyond this hydrophobic tun-
nel, up to the EL4 loop on the ER lumen face of the membrane is
highly conserved, so it is likely that the Dol-P lipid moiety could
bind to this surface. At the other end of the tunicamycin lipidmoi-
ety, the amide forms polar interactions with Asn185 and lies
close to Lys125, suggesting that the amide moiety partially
mimics the phosphate head-group of Dol-P (Figures 2G and 2H).
The DPAGT1 Catalytic Mechanism
Alternative mechanisms have been proposed for the PNPT
family including one-step, nucleophilic attack (Al-Dabbagh
et al., 2008) or two-step, double displacement via a covalent in-
termediate (Lloyd et al., 2004). We did not observe any covalent
modification of DPAGT1 in the presence of UDP-GlcNAc, nor did
we see release of UMP in the absence of Dol-P as might be pre-
dicted for a two-step mechanism. Also, the active site lacks suit-
ably placed residues that could act as a nucleophile. Therefore
the most probable mechanism involves direct nucleophilic
attack by Dol-P phosphate oxygen atom on the phosphorus
atom of the b-phosphate of UDP-GlcNAc, causing phosphate
inversion and loss of UMP (Figures 3B and 3C).
When bound to DPAGT1, UDP-GlcNAc adopts a bent-back
conformation, with the donor sugar lying below the phosphates,
rotated towards the uridine (Figure 2D). The pyranose ring is
inclined so that the O6 hydroxyl of the GlcNAc is within 3.1 A˚
of the O5B atom of the a-phosphate. This orientation presents
the b-phosphate of the UDP-GlcNAc to the position that would
be occupied by the phosphate of the Dol-P, exposing the lowest
unoccupied molecular orbital (LUMO) of its b-phosphate
electrophile for reaction with the Dol-P phosphateO-nucleophile
(Figures 3B and 3C).Cell 175, 1045–1058, November 1, 2018 1049
Providing the correct geometry for this one-step phosphoryl
transfer appears to be key to catalysis. Analyses of other enzy-
matic phosphoryl transfer reactions suggest that a bridging
Arg (in a very similar position to Arg301) and bridging metals (in
a very similar position to the Mg2+ ion) do not tighten the transi-
tion state but instead provide binding energy that optimizes ge-
ometry and alignment for attack (Lassila et al., 2011). They may
also preferentially favor the formation of trigonal bipyramidal ge-
ometry during nucleophilic attack. Similarly, despite classical
emphasis on reducing electrostatic repulsions between anionic
nucleophiles with anionic electrophiles, such as those present
in phosphoryl transfer (Westheimer, 1987), such effects are small
inmodel systems (Lassila et al., 2011). This suggests that the role
of Lys125, which would be close to the phosphate oxygens in
Dol-P, would be mainly to guide the phosphate into position.
The correct alignment of Dol-P for attack would be further facil-
itated by the ‘‘grip’’ provided by Trp122 holding the Dol-chain
into the tunnel observed in the tunicamycin,DPAGT1 complex.
Representative residues proposed to bind Dol-P, sugar and py-
rophosphate were probed by mutagenesis. Mutation of Mg2+-
chelating residues to Ala (Asn185Ala and Asp252Ala) reduced
DPAGT1 activity to 1.2%and 7%, respectively (Figure 3A). A con-
servative Asn185Asp mutation, expected to retain Mg2+-binding
activity, alsoablatedactivity (0.7%ofWT) suggestinganadditional
role for Asn185 in catalysis. The amide group of Asn185 lies
within 4 A˚ of the predicted Dol-P phosphate-binding site, forming
hydrogen bonds with the nucleophilic oxygen of Dol-P to guide
it towards the b-phosphate. Lys125 Mutations (Lys125Ala,
Lys125Glu, and Lys125Gln) near the Dol-P phosphate binding
site, all reduced the activity to below 2.2%, consistent with it play-
ing a critical guiding role. Interestingly, an Asp252Asn mutation
increasedactivity5-fold (Figure3A). Thismutation removesacoor-
dinating negative charge from the Mg2+, making it more electro-
positive and the b-phosphorus more electrophilic, potentially
increasing its susceptibility to nucleophilic attack.
Mutation of His302, which hydrogen bonds to the O4 oxygen
of GlcNAc in UDP-GlcNAc to hold it in its bent-back conforma-
tion, caused 98% loss of activity, consistent with it playing a
role in aligning the nucleophile to attach the b-phosphate. Finally,
mutations of Arg301, found in patients with CDG-Ij (Imtiaz et al.,
2012), that is part of the ‘‘pyrophosphate pincer’’ caused 95%
loss of activity.
Mutations in DPAGT1 in CMS and CDG
DPAGT1-CMS and CDG-Ij are recessive disorders, caused by
loss of DPAGT1 function (Table S1), through loss of enzymatic
activity, protein truncation or RNA splicing defects. Structures,
catalytic activity (Figure 4A), and thermostability measurements
(Figure 4B) for purified mutant proteins allowed us to examine
how DPAGT1 variants cause disease (Figures 4 and S3, Table
S1). Surprisingly, in most cases mutated DPAGT1 protein had
close to WT thermostability (Figure 4B), suggesting correct
folding. Only two (Ile29Phe and Arg218Trp, Basiri et al., 2013; Iq-
bal et al., 2013) gave protein that was too unstable to purify, due
to insertion of large hydrophobic sidechains either at the ER sur-
face or in the core of the protein (Figure 4C).
Many CMS patients have compound heterozygous mutations,
and in general one allele had a much greater impact on DPAGT11050 Cell 175, 1045–1058, November 1, 2018function, with either loss of at least 75% of the WT catalytic ac-
tivity (Leu120Met, Gly192Ser, Met108Ile, Figure 4A, Table S1) or
protein quantity (e.g., truncation: Thr234Hisfs*116, (Belaya et al.,
2012); low protein yield: Ile29Phe (Klein et al., 2015); exon skip-
ping: Leu120Leu (Selcen et al., 2014). However, expressed pro-
tein from the second allele had 50%ormoreWT catalytic activity
(Val117Ile, Pro30Ser, Val264Met) or even increased activity
(Val264Gly and Gly160Ser, Belaya et al., 2012) (Figure 4B,
Table S1). The only homozygous CMS mutation, Arg218Trp
(Basiri et al., 2013), gave protein that was too unstable to purify.
Patients with the more severe CDG-Ij disease often had signifi-
cant loss of function for both alleles, with less than 25% activity
(Leu168Pro, Tyr170Cys, Arg301His, Arg301Cys), low protein
yield/stability (Ile29Phe), or disrupted splicing (with WT activity
and thermostability for the purified protein, e.g., Ala114Gly,
Wu¨rde et al., 2012). The Leu385Arg (Carrera et al., 2012) and
Ile69Asn (Timal et al., 2012) mutations are unusual in that they
did not show loss of stability or activity, suggesting that splicing
changes should be investigated.
As expected, mutations with less than 25% activity generally
lie in or near the substrate-binding regions. In two variants found
in patients with CDG-Ij (Arg301His and Arg301Cys, Carrera et al.,
2012; Imtiaz et al., 2012), the Arg301 that ‘‘pincers’’ the UDP-
GlcNAc pyrophosphates is mutated (Figures 2D and 2F) and
these mutations gave reduced thermostabilization by UDP-
GlcNAc (Figure 4D), confirming a role in UDP-GlcNAc binding.
Similarly, the CMS variant Leu120Met lies close to the Dol-P/
UDP-GlcNAc interface on the critical CL3 loop that forms one
side of the active site (Figure 4E) and the variant Gly192Ser
(Belaya et al., 2012) lies within the highly conserved CL5 loop
in the uridyl recognition pocket (Figure 4E) where it would
disrupt substrate binding. Two CDG-Ij mutations (Leu168Pro
and Tyr170Cys, Iqbal et al., 2013; Wu et al., 2003) are of partic-
ular interest as they lie on the ER side of themembrane, at the top
of the predicted Dol-P binding site, an extensive, conserved
intramembrane groove between TMH4, TMH5, and TMH9,
below the EL4 loop (Figure 4F). Both mutations cause a reduc-
tion in thermostabilization by Dol-P, confirming their involvement
in Dol-P binding. The Met108Leu mutation lies within a hydro-
phobic cluster in the core of DPAGT1 where a mutation would
disrupt the positions of TMH4 and TMH5, which form the back
of the Dol-P binding site (Figure 4F). Conversely, many of themu-
tations that maintain at least 50% ofWT activity lie on the protein
surface (e.g., Pro30Ser, Ala114Gly, Val117Ile) and involve small
sidechain changes (Figure 4C).
Given that DPAGT1-CMS is a recessive disorder, wewere sur-
prised to find an increased enzymatic activity with the Val264Gly
and Gly160Ser variants. Val264 is mutated to either Gly or Met
(Selcen et al., 2014), giving either a 2.5-fold increase or a slight
(18%) decrease in catalytic activity. Val264 is located on TMH8
in the core of the protein adjacent to TMH3/4 (Figure 4G).
Comparing the WT and Val264Gly structures showed a small
(1–1.5 A˚) movement at the C-terminal end of TMH4b towards
TMH8 (Figure 4G), which would affect both the dimer interface
and the exact position of EL4, which forms the top of the Dol-P
lipid-binding site. Conversely, the Val264Met variant would be
poorly accommodated at this buried site. As the Gly160Ser mu-
tation lies in the disordered EL4 luminal loop (Figure 4F), it is
Figure 4. DPAGT1 CMS and CDG-Ij Missense Variants Analyses
(A) Relative activity and (B) thermostability for DPAGT1 missense variants found in CMS (dark grey) or CDG-Ij (mid grey). WT activity/stability is indicated by an
orange line. Mutations are colored in panels A, D, E-G as follows: 25% or less activity: red; 50%–100% WT activity: pink; >WT activity: green; instability on
purification: cyan; confirmed splicing variants indicated with a *; Spl: unknown splicing variant. For all measurements n=9.
(C) Location of variants mapped onto tunicamycin (purple) complex, colored as above.
(D) Changes in thermostabilization of selected variants by substrates UDP-GlcNAc and Dol-P (n=9).
(E) Location of variants near UDP-GlcNAc binding site.
(F) Variants near predicted Dol-P binding site. Dol-P (pale green) has been modelled based on the tunicamycin lipid tail.
(G) Environment of Val264. Structures of WT (grey) and V264G variant (orange) are shown illustrating the subtle conformational difference in TM4b and EL4.
For all panels data presented are means ± SD.unclear why the activity increases. Since these missense vari-
ants cause an unexpected increase in enzyme activity, we
explored other causes of pathogenicity. Tissue from muscle bi-
opsies were unavailable, so we used the ‘‘exon trap’’ system
to detect abnormal RNA splicing. Both mutations, c.478G>A,
p.Gly160Ser, and c.791T>G, p.Val264Gly, gave rise to abnormal
RNA splicing of their respective RNA transcripts (Figure S3), thus
explaining the pathogenicity of these variants.
Development of Non-toxic ‘‘TUN-X,X’’ Analogues of
Tunicamycin
The potent ‘‘off-target’’ inhibitory effects of tunicamycin on
DPAGT1 prevent its use as an antibiotic. We used structural
data coupled with genetics to design analogues (TUN-X,X)
that retained anti-microbial activity yet no longer inhibited
DPAGT1. We previously cloned and sequenced the tunicamycin
biosynthetic gene cluster (tun) from Streptomyces chartreusis
and expressed it heterologously in Streptomyces coelicolor
(Wyszynski et al., 2010; Wyszynski et al., 2012). The cluster con-
tains 14 genes, tunA-N. In-frame deletion mutations in all of thecloned tun genes in S. coelicolor (Widdick et al., 2018) revealed
new insights into tunicamycin biosynthesis. Interestingly, dele-
tion of tunI and tunJ, encoding components of an ABC trans-
porter conferring immunity to tunicamycin, could only be
achieved with mutations elsewhere in the tun gene cluster.
Sequencing of one of the DtunI mutants revealed a G-to-A
missense suppressor mutation in tunC, resulting in a Gly70Asp
substitution in the N-acyltransferase TunC that attaches the lipid
of tunicamycin. This presumed loss of function mutation abol-
ished antibacterial activity, consistent with a key role for the lipid
chain in the biological activity of tunicamycin.
We therefore designed a semi-synthetic strategy to access
systematically ‘‘lipid-altered’’ variants of tunicamycin based on
tunicamine scaffold TUN (Figure 5A). Large-scale fermentation
of S. chartreusis NRRL 3882 (Doroghazi et al., 2011) (Methods
S1) allowed access to crude tunicamycin on a multi-gram scale.
Degradative conversion (Ito et al., 1979) of tunicamycin gave un-
functionalized core scaffold TUN. Critically, since the nucleo-
base of tunicamycin is hydrolytically sensitive, the creation of
mixed Boc-imides at positions 10ʹ and 2ʹʹ allowed mild, selectiveCell 175, 1045–1058, November 1, 2018 1051
Figure 5. Semi-synthetic Synthesis and Antibacterial Effects of TUN-X,X Analogues
(A) Semi-synthetic strategy for TUN mimics.
(B–D) MIC obtained from micro-broth dilution antimicrobial susceptibility tests of (B) B. subtilis EC1524, (C) B. cereus ATCC11778, (D)Mtb H37Rv (ATCC27294)
cultured in 7H9/ADC/Tw (black), or GAST/Fe (grey) media (n=3). For all panels data presented are means ± SDdeamidation on a gram-scale (see Supplemental Information SI
2). Chemoselective carbodiimide- or uronate-mediated acyla-
tion allowed direct lipid-tuning in a systematic, divergent manner
through modification at 10ʹ-N and/or 2ʹʹ-N, yielding a library of
novel analogues, TUN-X,X varying in chain length by one car-
bon, from C7 to C12 (TUN-7,7 to TUN-12,12, Figure 5A) with a
typical purity of >99% (see Methods S1) as judged by NMR
and/or HPLC.1052 Cell 175, 1045–1058, November 1, 2018TUN Analogues Show Potent Antimicrobial Activity
against a Range of Bacteria
Weevaluated the analogues (TUN-7,7, -8,8, -9,9, -10,10, -11,11,
-12,12) for potency against a range of Gram-negative and
Gram-positive bacteria that cause infections in hospitals
(Staphylococcus, Pseudomonas, and Escherichia), as well as
reference bacteria (Bacillus, Staphylococcus, andMicrococcus)
used in previous tunicamycin bioactivity studies (Ward, 1977).
Kirby-Bauer disc diffusion susceptibility tests (Figures S4A–
S4E), revealed potent activity against Bacillus subtilis (EC1524)
and opportunistic pathogen Bacillus cereus (ATCC 11778).
There was a weaker but significant effect on the pathogenic bac-
teria Staphylococcus aureus (ATCC 29219) and Pseudomonas
aeruginosa (ATCC 27853); the latter is a strain resistant to natural
tunicamycin. No activity was seen againstMicrococcus luteus, a
bacterium noted to have some resistance to tunicamycin (Ward,
1977). Consistent with the critical role of the lipid, none of the
non-lipidated analogues (e.g., TUN or TUN-Ac,Ac) or synthetic
intermediates showed any activity. Lipid-length (X = 7, 8.12)
in the TUN-X,X analogues systematically modulated activity;
the most potent analogues TUN-8,8 and TUN-9,9 were those
with C8 and C9 chain lengths.
The minimal and half maximal inhibitory concentrations
(MIC and IC50) and minimal bactericidal concentrations (MBC)
were determined by both a micro-broth dilution test and
drop plate test, respectively (Figures 5B and 5C, Figures
S5F–S5J, Table S3). Only lipidated variants (tunicamycin and
TUN-X,X) displayed antibacterial activity, with MICs down
to 0.02 ± 0.01 mg/ml for TUN-9,9 against B. subtilis and
0.33 ± 0.11 mg/ml against B. cereus, with TUN-10,10.
TB, through its etiological agent Mycobacterium tuberculosis
(Mtb) is a global concern. Testing of the lipid-altered analogues
(TUN-7,7 to -12,12) against pathogenic Mtb strain H37Rv re-
vealed striking MIC values (0.03 ± 0.001 mg/ml in minimal growth
medium and 0.22 ± 0.02 mg/ml in rich 7H9-based growth me-
dium) for TUN-9,9: some 5-fold more potent than even tunica-
mycin itself (Figure 5D, Table S4).
The on-target effect of tunicamycin analogues was explored
by multiple approaches. Firstly, TUN-8,8-resistant Mtb mutants
(Methods S1) carried mutations in Rv0751c (mmsB, 3-hydroxyi-
sobutyrate dehydrogenase), an enzyme in fatty acidmetabolism,
suggesting possible inactivation of TUN-8,8 by destruction of
fatty acid/lipid or an intergenic mutation between Rv2980 and
Rv2918c (the central D-alanine-D-alanine ligase ddlA involved
in peptidoglycan (PG) synthesis), suggesting possible regulation
of this key PG biosynthetic enzyme (perhaps via small regulatory
noncoding RNA). Secondly, macromolecular incorporation
assay using 14C-glucosamine as radiolabeled precursor (Fig-
ure S5A) confirmed that TUN-8,8 and tunicamycin have similar
effects on PG biosynthesis, suggesting that they act on the
same target. Thirdly, extracellular release of green fluorescent
protein (GFP) from Mtb expressing GFP showed lytic effects of
TUN-8,8, even outstripping those of tunicamycin (Figure S5B),
consistent with on-target PG inhibition activity. Finally, fluores-
cently-labeled vancomycin (Daniel and Errington, 2003; Tiyanont
et al., 2006) revealed similar phenotypes (Figure S5C) following
treatment with TUN-8,8 or tunicamycin with disrupted, non-uni-
form cell-wall, consistent with targeting of the PG pathway.
Together these data suggested that TUN-8,8 is inhibiting the
same target as tunicamycin in Mtb.
Lipid-altered TUN-X,X Analogues are Non-toxic to
Eukaryotic Cells
We evaluated the effect of TUN-7,7 to -12,12 and corresponding
synthetic intermediates on representative human cell lines from
liver (HepG2), kidney (HEK293), and blood (Raji) cells where24 hour incubation with tunicamycin showed both clear cytotox-
icity (Figures 6A–6C, Figure S6) andmorphological changes (Fig-
ure 6D, Figures S6B–S6D) consistent with prior observations
(Takatsuki et al., 1972). Cell-cycle analysis (Figures 6E and
S6A) suggested cell death coincides with decline in G0/1 phase
populations with an LC50 100 mg/ml.
Consistent with a mode of action requiring lipidation for
toxicity, all non-lipidated variants (TUN core and synthetic inter-
mediates) displayed no significant adverse effects; these vari-
ants do not act upon either bacteria or mammalian cells in any
potent manner.
In contrast to tunicamycin’s toxicity (LD50 = 51.25 ± 31.27,
44.74 ± 4.73, 26.82 ±11.46 mg/ml for HEK293, HepG2 and Raji
cells, respectively, Figures 6A–6C and Table S5) the designed
TUN-X,X variants TUN-7,7 to -12,12, with altered lipids, showed
mild or negligible toxicity (LD50 > 400 mg/ml, saturation) towards
mammalian cells. A high level (>75%) of viable cells with no
morphological changes were observed after 24 hours (Fig-
ure S6A) for HepG2 or HEK293 cells (400 mg/ml, saturation).
Moreover, no variation in cell cycle was observed, with healthy
G0/1 populations maintained at even highest concentrations
(Figure 6E, Figure S6A).
The mechanistic origin of reduced toxicity was tested
in vitro with purified DPAGT1 enzyme. Whilst native tunicamycin
completely inhibited DPAGT1, TUN-8,8 and TUN-9,9 had a
negligible effect (Figure 6F), consistent observations for glyco-
sylation of model protein (Figures S6E–S6G). Notably, synthetic
reinstallation of a single C8 lipid into analogue TUN-8,Ac
restored inhibitory activity towards DPAGT1 (Figure 6F), consis-
tent with our design and the critical role of the second lipid pre-
venting binding to DPAGT1. Given that in patients with CMS, a
loss of the activity of one allele is not sufficient to cause disease,
it is likely that a reduction in activity by <10%, caused by the
TUN-X,X analogues, is unlikely to cause significant toxicity dur-
ing a short-term treatment. Together these results confirmed our
hypothesis that systematic ‘‘lipid alteration’’ could create tunica-
mycin analogues in which mammalian cytotoxicity is separated
from antibacterial effects.
A Molecular Explanation for Differences in TUN-X,X
Analogue Binding to DPAGT1 and MraY
Comparison of the structures of the complexes of tunicamycin
with DPAGT1 and MraY (Hakulinen et al., 2017; Yoo et al.,
2018; this work) gave an explanation for selectivity of analogues
on MraY over DPAGT1. The MraY tunicamycin binding site has a
more open, shallow surface than in DPAGT1; in the latter the lipid
tail is completely enclosed by Trp122 adjacent to the active site
(Figure 6G). The MraY binding site has a disordered loop CL1, a
longer TMH9 and a relatively short CL9 region, with only one
short a-helix (Figure 1G). In contrast, DPAGT1 has an ordered
CL1 which folds over the UDP-binding site. It has a shorter
TMH9, followed by a loop and extended strand (residues
Gln292 to Arg306) (Figure 1F), which fold over tunicamycin,
forming numerous interactions, (e.g., with Arg301, His302,
Arg303, Figures 2G and 2H). This extended structure is stabilized
by its interactions with the rest of the CL9 domain, a feature
found only in eukaryotes.
The N20 0 in GlcNAc is the attachment site of the second lipid
chain in TUN-X,X analogues—it occupies distinct environmentsCell 175, 1045–1058, November 1, 2018 1053
Figure 6. TUN-X,X Analogues are Not Toxic to Cultured Human Cells
(A–C) Dose response curves from cell proliferation assays with (A) HEK293, (B) HepG2 and (C) Raji cells with tunicamycin and analogues (n=3 in each case).
(D) Effect of 400 mg/ml (saturating) tunicamycin, TUN-8,8 and TUN-9,9 on HEK293 cell morphology.
(E) Effects of tunicamycin, TUN-8,8 and TUN-9,9 on HEK293 cell cycle (n=3).
(F) Effects of tunicamycin and TUN-X,X analogues on DPAGT1 catalytic activity (n=9).
(G) DPAGT1 lipid-binding site, showing the restrictive tunnel with tunicamycin bound.
(H) More open MraY lipid-binding site (PDB: 5JNQ), with modelled lipid chains shown with lower contrast.
For panels (A–C) and (E), data presented are means ± SEM. For (F), data presented are means ± SD.in the two proteins. In DPAGT1 it is enclosed by the loop at the
end of TMH9, and by a tight ‘‘gating’’ cluster of side chains
from Trp122, Ile186, Leu293, Cys299, and Arg303 (Figure 6G).
By contrast, in MraY, there is a 10 A˚ gap between Pro108 on
TMH4a and Val272 on TMH9, providing ample space for more
than one lipid chain to be attached to the amines in TUN-X,X
analogues (Figures 6G and 6H).1054 Cell 175, 1045–1058, November 1, 2018Lipid-altered TUN-X,Xs Show Efficacy against Mtb
in Mice
The enhanced therapeutic index of the TUN-X,X analogues
in culture (Table S6) suggested strong potential in treating
mammals. Toxicity and efficacy were probed in infection
models of Mtb both in cellulo and in vivo. First, as a stringent
in cellulo test of the ability to treat infection, TUN-8,8,
Figure 7. Tunicamycin Analogues Eradicate Mtb during Host Pathogenesis
(A) Efficacy of tunicamycin analogues in macrophages. Infected J774A.1macrophages were treated with compounds (1x and 10xMIC) for 3 or 7 days after which
bacterial burdens were counted (n=3).
(B) Microsomal stability of the tunicamycin analogues in human (black) and mice (grey) liver microsomes assessed over a period of 30 mins (n=3).
(C) Mouse blood serum TUN-8,8 concentrations after a single intra-peritoneal injection of 30 mg/kg (n=5).
(D) Efficacy of TUN-8,8 in reducing lung bacterial burdens in Mtb-infected mice after 2 weeks of treatment.
(E) Efficacy of TUN-8,8 in reducing spleen bacterial burdens in Mtb-infected mice following 2 weeks of treatment. Unpaired t test for the TUN-8,8 and vehicle
control group p value of 0.0017 in lungs and 0.01 in spleens.
For all panels (A–C), data presented are means ± SD. For panels (D) and (E), the individual median calculated for each individual mouse organ with standard error
of the mean calculated for each group is shown.TUN-9,9, TUN-10,10, and TUN-11,11 were used to treat Mtb-
infected macrophages (Figure 7A), which showed that these
analogues reduced intracellular bacterial burdens by 1- and
2-logs at 1 3 and 10 3 MIC, respectively.
Second, microsomal (human and mouse) stability (Figure 7B)
suggested good metabolic survival of TUN-8,8 to -11,11, which
was confirmed by in vivo pharmacokinetics in mice (Figure 7C).
This revealed good bioavailability of TUN-8,8 following intraper-
itoneal (ip) delivery with acceptable blood plasma exposures. In
human plasma protein binding assays, 98.2% was bound. Next,
tolerance testing of TUN-8,8 in uninfected mice (n=5) over
10 days at daily doses of 30 mg.kg-1 (ip) showed no signs of
toxicity, in striking contrast to tunicamycin. Finally, antitubercular
activity was demonstrated in Mtb-infected mice. Treatment of
Mtb-infected mice (n=10) over two weeks (10 mg.kg-1, ip)
revealed an almost 10- and 5-fold reduction in bacterial burdens
in lungs (Figure 7D) and spleens, respectively, (Figure 7E)
compared to mice receiving vehicle control. Notably, despite
the tolerability at 30 mg.kg-1 up to 10 days in uninfected animals,clinical signs of toxicity in infected mice precluded any longer-
term testing beyond 2 weeks. The origins of this toxicity in
diseased animals are unclear but suggest that further optimiza-
tion of TUN-X,X analogues and/or their formulation, may be crit-
ical to disease-weakened animals. TUN-X,X analogues are
therefore unoptimized but promising, proof-of-principle, leads
rather than, as yet, optimized antibiotic drugs.
DISCUSSION
Structures of DPAGT1 allowed us to explain the mechanism of
this key enzyme in protein N-glycosylation. We showed that
missense variants in DPAGT1 associated with CMS and CDG-Ij
alter DPAGT1 function via diverse mechanisms. For many cases
of milder CMS disease, severely reduced activity from one allele
is combined with an allele with partial activity. In two cases,
Val264Gly and Gly160Ser, it appeared that errors in splicing
reduced the levels of correct mRNA were partially compensated
by 2-fold increases in enzymatic activity. In CDG-Ij, either oneCell 175, 1045–1058, November 1, 2018 1055
allele produces protein with 20% activity or, alternatively, two
alleles producing 5%–10% activity, leading to much greater
disease severity. In all cases some active protein is present,
with a threshold of symptoms and increasing disease severity
between no disease at 50% activity and severe disease
with 5%–10% of activity. It is significant that DPAGT1 activity
can be increased by point mutations at single sites, suggesting
it may be possible to increase enzymatic activity and/or
modulate stability with small molecules, e.g., pharmacological
chaperones (Convertino et al., 2016; Sa´nchez-Ferna´ndez
et al., 2016).
DPAGT1 is an ‘‘off-target’’ for the natural bactericidal tunica-
mycin. Comparison of the human PNPT DPAGT1 and bacterial
PNPT MraY structures revealed a gating loop (residues
Cys299-Arg303) in DPAGT1 next to where the N-20 0 atom of
tunicamycin binds, that is absent in the more open structure
of MraY. This difference allowed design of analogues TUN-X,X
with two lipid chains targeted to bind MraY, but not DPAGT1.
This circumvented the toxicity problem normally observed with
tunicamycin. Additive modes of action against other carbohy-
drate-processing enzymes, such as Mtb WecA or TagO/TarO
(Ishizaki et al., 2013); (Santa Maria et al., 2014), may also be
important for the effects of the analogues.
Mtb is responsible for 1.3 million deaths per annum with
increasing spread of drug resistant strains requiring new strate-
gies (Young et al., 2008; Zumla et al., 2013). We have shown that
the TUN-X,X lipid analogues have much lower toxicity than tuni-
camycin itself, are effective in killing Mtb in vitro, in cellulo, and
in vivo. The analogues did show some toxicity in mice after
more than 2 weeks in diseased (but not healthy) animals, yet
they are still much less toxic than tunicamycin. While these
lead versions of the TUN-X,X lipid analogues are not as effective
as the frontline drugs rifampicin and isoniazid in macrophages
and in mice in vivo, details of the effects in mice are often not
recapitulated in humans. In addition, we do not yet have data
on intracellular uptake in animals, which may be affecting the
outcome. MICs show these compounds are excellent leads for
the design of novel antibiotics with a new mechanism of action.
TUN-X,X lipid analogues are effective antibacterials, with limited
toxicity in human cells and in mice (at least with short term
dosing), and these and other analogues (Price et al., 2017b)
(Price et al., 2017a) suggest a novel approach to development
of antibiotics against Gram-positive bacteria.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Bacterial and Virus Strains
MAX Efficiency DH10Bac Thermo Fisher Cat# 10361012
Biological Samples
Mouse liver microsomes Sigma Cat# M9441
Human liver microsomes Sigma Cat# M 0317
Chemicals, Peptides, and Recombinant Proteins
Tunicamycin Sigma-Aldrich Cat# T7765; CAS: 11089-65-9
uridine diphosphate n-acetyl [1-14C] D-glucosamine American Radiolabeled Chemicals Cat# ARC 0151
Rifampicin Sigma-Aldrich Cat# R3501
Uridine 50-diphospho-N-acetylglucosamine sodium salt Sigma-Aldrich Cat# U4375
C95-Dolichyl-MPDA Larodan Cat# 67-1095
H. sapiens DPAGT1 (1-408, N-terminal 6 x HIS tag,
TEV cleavage site)
This work N/A
H. sapiens DPAGT1 (1-408, Val264Gly, N-terminal
6 x HIS tag, TEV cleavage site)
This work N/A
Critical Commercial Assays
MemGold2 HT-96 screen Molecular Dimensions Cat# MD1-64
Deposited Data
H. sapiens DPAGT1 (WT) This work PDB: 6FM9
H. sapiens DPAGT1 (Val264Gly) This work PDB: 5LEV
H. sapiens DPAGT1 (Val264Gly) + UDP-GlcNAc + Mg2+ This work PDB: 6FWZ
H. sapiens DPAGT1 (Val264Gly) + Tunicamycin This work PDB: 5O5E
Experimental Models: Cell Lines
Spodoptera frugiperda (Sf9) insect cells Thermo Fisher Cat# 11496015; RRID:CVCL_0549
HepG2 ATCC Cat# ATCC HB-8065
HEK293 ATCC Cat# ATCC CRL-1573; RRID:CVCL_0045
Raji ATCC Cat# ATCC CCL-86; RRID:CVCL_0511
J774A.1 ATCC Cat# ATCC TIB-67; RRID:CVCL_0358
Experimental Models: Organisms/Strains
Streptomyces chartreusis DSMZ Cat# 41447
Bacillus subtilis EC1524 John Innes Centre N/A
Micrococcus luteus John Innes Centre N/A
Bacillus cereus DSMZ Cat# 345
Escherichia coli Thermo Fisher Cat# ATCC 25922
Staphylococcus aureus Thermo Fisher Cat# ATCC 29219
Pseudomonas aeruginosa Thermo Fisher Cat# ATCC 27853
Mycobacterium tuberculosis H37Rv ATCC Cat# ATCC27294
C57Bl/6 mice Taconic B6
Oligonucleotides
Oligonucleotides See table S8 B6
Recombinant DNA
pFB-LIC-Bse This paper N/A
DPAGT1 gene Source BioScience LifeSciences IMAGE:2821845
pMSP12::GFP Addgene Cat# 30167
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Software and Algorithms
Prism 7 GraphPad www.graphpad.com
X-ray Detector Software (XDS) (Kabsch, 2010) http://xds.mpimf-heidelberg.mpg.de/
CCP4 Suite (Winn et al., 2011) http://www.ccp4.ac.uk/
PHYRE2 webserver (Kelley et al., 2015) http://www.sbg.bio.ic.ac.uk/phyre2
MR_ROSETTA (phenix.mr_rosetta) (Terwilliger et al., 2012) https://www.phenix-online.org/
documentation/reference/mr_rosetta.html
PHENIX (Adams et al., 2010) https://www.phenix-online.org/
BUSTER (v.2.10.2 & v2.10.3) (Bricogne et al., 2017) https://www.globalphasing.com/buster/
COOT (Emsley et al., 2010) https://www2.mrc-lmb.cam.ac.uk/
personal/pemsley/coot/
PyMOL Schro¨dinger, LLC https://www.pymol.org/
MOLPROBITY (Chen et al., 2010) http://molprobity.biochem.duke.edu/
STARANISO Global Phasing Ltd http://staraniso.globalphasing.org
PDB2PQR (Dolinsky et al., 2004) http://nbcr-222.ucsd.edu/pdb2pqr_2.0.0/
UCSF Chimera (Pettersen et al., 2004) https://www.cgl.ucsf.edu/chimera/
Mass spectrometry software Qual Browser Thermo Fisher Xcalibur 2.2CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact (Liz
Carpenter, liz.carpenter@sgc.ox.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Bacteria
The strain and source of all the bacteria used in this study are detailed in the key resources table.
Sf9 cell culture
Sf9 cells were cultured in Sf 900 II SFMmedium in a 27 C incubator, rotating at 100 rpm. Sf9 cells were derived from the epithelium of
a pupal female Spodoptera frugiperda.
HepG2 and HEK293 cell culture
HepG2 and HEK293 cells were cultured in DMEM medium supplemented with 10% heat inactivated fetal bovine serum (FBS, v/v).
The cultures were maintained in a humidified incubator at 37 C in 5%CO2/95% air. FBS was reduced to 2% for the cell proliferation
assay. HEK293 cells were female, and HepG2 cells were male.
Raji cell culture
Raji cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal bovine serum (FBS, v/v). The cultures
were maintained in a humidified incubator at 37 C in 5% CO2/95% air. FBS was reduced to 2% for the cell proliferation assay. The
Raji cells used were male.
J774A.1 cell culture
J774A.1 cells are female mouse monocyte/macrophage cell type grown in DMEM GlutaMAX (Gibco) supplemented with 10% (v/v)
heat inactivated fetal bovine serum, 20 mM HEPES and 0.5 mM sodium pyruvate. Cells were maintained in 75 cm2 flasks and sub-
cultured (1:5) by scraping. The cultures were maintained in a humidified incubator at 37 C in 5% CO2/95% air.
Mice
Mouse studies were carried out in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health under Animal study protocol numbers LCID 4E. The NIAID Animal Care and Use Committee (NIAID ACUC), a federally
mandated committee, approved and oversaw all animal studies done under LCID4E and ensured that all work complied with the
U.S. Government Principles for the Utilization and Care of Vertebrate Animals, the Public Health Service (PHS) Policy on Humanee2 Cell 175, 1045–1058.e1–e9, November 1, 2018
Care and Use of Laboratory Animals, the Animal Welfare Act, and all applicable Animal Welfare Regulations. For all studies, murine-
pathogen-free 8-week old naı¨ve wild-type female mice were used. Mice were housed in a biosafety level 3 vivarium with 4-5 animals
per cage. Animals were not subjected to water or food restrictions andmonitored twice daily by veterinary staff for welfare and health
with distressed animals as evidenced by signs of lethargy, weight loss or pain, euthanized according the ASP guidelines.
METHOD DETAILS
Cloning and expression
The WT DPAGT1 cDNA sequence was cloned into the pFB-LIC-Bse expression vector (available from the SGC) with an N-terminal
purification tag with a tobacco etch virus (TEV) protease cleavage site, and a 6x His purification sequence. Baculoviruses were
produced by transformation of DH10Bac cells. Spodoptera frugiperda (Sf9) insect cells in Sf-900 II SFM medium (Thermo Fisher)
were infected with recombinant baculovirus and incubated for 65 h at 27 C in shaker flasks.
Site Directed Mutagenesis
DPAGT1 point mutations were generated using three different methods. The CMS causing mutations were created using the
QuickChange site-directed mutagenesis kit (Agilent) according to manufacturer’s instructions; the CDG-Ij causing mutations were
generated using the two-step overlap extension PCR method, and the mechanistic mutations were created using the Megaprimer
method of site-directed mutagenesis. In the first step of the two-step overlap extension PCR method, the 5’ and 3’ portions of
DPAGT1 were amplified in separate reactions using LIC-adapted external primers with internal mutagenic primers. In the second
step, the first round products were combined with the LIC-adapted primers to amplify the complete DPAGT1 gene, including the
desired mutations. The Megaprimer method uses a single oligonucleotide primer containing each desired mutation was synthesized
(Eurofins Genomics). A touchdown polymerase chain reaction, using the mutagenic internal primer and either a 5’ or 3’ external
primer, was used to generate a ‘‘megaprimer’’: a truncated gene fragment that contains the mutation. A second PCR reaction, using
the megaprimer and the opposite external primer, was performed to generate the full-length mutated DPAGT1. The PCR products
generated from the 3 different methods were then cloned into the pFB-LIC-Bse expression vector via ligase-independent cloning.
A full list of the oligonucleotide primers and vectors used in this study can be viewed in the Table S8.
Purification of DPAGT1 protein for structural and functional studies
Cell pellets from 1 litre of insect cell culture were resuspended in 40ml in lysis buffer (50 mM HEPES, pH 7.5, 5 mM MgCl2, 200 mM
NaCl, 5 mM imidazole, 2 mM TCEP (added fresh), 5% glycerol, Roche protease inhibitors (1 tablet per 40ml buffer, added on day of
use) in warm water, mixing constantly to keep the sample cold. Cells were lysed by two passes through an EmulsiFlex-C3 homog-
enizer (Aventin). Protein was extracted from cell membranes by incubation of the crude cell lysate with 1% (w/v) OGNG and 0.1%
(w/v) CHS for 1 h at 4C on a rotator. Cell debris and unlysed cells were removed by centrifugation at 35,000 g for 45 mins.
Immobilized metal affinity chromatography was then used to purify the detergent-solubilized His-tagged protein by batch binding
to Co2+ charged TALON resin (Clontech) at 4 C for 1 h. The resin was then washed with wash buffer (WB: 50 mM HEPES
(pH 7.5), 5mM MgCl2, 10 mM imidazole (pH 8.0), 200 mM NaCl , 2 mM TCEP (added fresh), 5% Glycerol, 0.18% OGNG, 0.01 8%
CHS, 0.0036% cardiolipin) and the protein was eluted with WB supplemented with 250 mM imidazole (pH 8.0). The eluted protein
was desalted using PD-10 columns (GE Healthcare) pre-equilibrated with gel filtration buffer (GFB: 20 mM HEPES (pH 7.5) ,
5 mM MgCl2, 200 mM NaCl, 2 mM TCEP, 0.12% OGNG, 0.012% CHS, 0.0024% cardiolipin). Desalted protein was subsequently
treated with 10:1 TEV protease (w:w, protein:enzyme) overnight at 4 C. The TEV protease treated protein was separated from
the 6-His-tagged enzymes and uncleaved DPAGT1 by incubation for 1 h with Talon resin (prepared as described above) at 4 C
for 1h. The resin was collected in a column, the flowthrough collected and the protein sample was centrifuged at 21,500 rpm in a
Beckman TA25.5 rotor for 10 min at 4 C. The supernatant was then concentrated to 0.5 ml using a 30 kDa cutoff PES concentrator
(Corning), with mixing every 5 mins during concentration. The concentrated protein was then centrifugated at 20,000 g for 10 min,
then further purified by size exclusion chromatography (SEC) on a Sepharose S200 column (GE Healthcare) in GFB. The peak frac-
tions were pooled and concentrated using a Sartorius 2ml PES 50 kDa concentrator (pre-equilibrated with GFB without detergent),
at 3220 g. The protein was centrifuged at 20,000g for 15 mins, then flash frozen in liquid nitrogen. The final concentration was
20-30 mg/ml. Denaturing LC-MS was performed on purified protein obtained from each purification as described below. A mass
of 46177 Da was obtained for the WT protein, which matches the DPAGT1 monomer (with an additional N-terminal Serine residue
from the TEV cleavage site). Similarly the Val264Gly mutated protein gave a mass of 46135 Da. Each mutated gene was sequenced
and the purified protein was subjected to denaturing, intact mass spectrometry. In each case the predicted sequence and mass was
observed for the mutated gene and protein. In all cases the monomer mass was observed, and there was no evidence for covalent,
disulphide-linked dimers. When DPAGT1 was purified in the absence of reducing agents, the same monomer mass was observed.
In no case did we observe a peak with the mass of a covalent, disulphide-bonded dimer.
Denaturing LC-MS
Intact mass of detergent solubilized DPAGT1 was determined as follows. Samples were diluted to a final concentration of 8-20mg/ml
in 30%methanol, 0.1% formic acid. Fifty ml was injected on to a 1290 UPLC coupled to a 6530 QTOFmass spectrometer fitted with aCell 175, 1045–1058.e1–e9, November 1, 2018 e3
ZORBAXStableBond 300C3, 2.1 x 150mm, 5 mmHPLC column (Agilent Technologies, Santa Clara, USA). Solvent Awas 0.1% formic
acid in HPLC grade water; solvent B was 0.1% formic acid in LC-MS grade methanol (Fisher Scientific, Loughborough, UK). Initial
conditions were 30% B at 0.5 ml/min. After 1 min a methanol gradient was applied from 30% to 95% over 7 min. Elution was
then isocratic at 95% B for 2 min, followed by a further 2 min equilibration at 30% B. Complete separation was achieved between
detergent (elution 6.2-8.0 min) and protein (elution 8.2-9.5 min). The mass spectrometer was operated in positive ion, 2 GHz detector
mode. Source parameters were drying gas 350 C, flow 12 l/min, nebulizer 60 psi, capillary 4000 V. Fragmentor was 250 V, collision
energy 0 V and data acquired from 100-3200 m/z. Data analysis was performed using Masshunter Qualitative Analysis B0.7 propri-
etary software and deconvolution performed using the Maximum Entropy algorithm.
Radiolabeled substrate enzyme activity assay
2 ml of 2 mM DPAGT1 WT or mutant proteins in GFB buffer supplemented with 5mM extra MgCl2, 1% OGNG/CHS/cardiolipin and
dolichyl monophosphate was combined with 2 ml of UDP-N-acetyl [1-14C] D-glucosamine in the same buffer and incubated at 37
C on a heat block for 21 min. The reaction was terminated by the addition of 6 ml of 100% methanol and immediately transferred
onto ice. 1 ml of sample was spotted onto a silica coated TLC plate in triplicate and run with a mobile phase consisting of chloroform,
methanol, andwater at a 65:25:4 ratio respectively. After the run, the TLC plate was dried thoroughly, wrapped in cling film, incubated
with a phosphor imaging substrate for 4 days, then phosphor imaged using a Biorad. The pixel density of the spots corresponding
to the hydrophobic product was divided by combined pixel density of the product and the substrate and multiplied by the known
concentration of substrate added to ascertain the amount of product formed.
Thermostability assays for DPAGT1 WT and mutant proteins
Samples with a volume of 40 ml were prepared containing 0.5 mg/ml protein and 50 mM compound or 5% DMSO in GFB. A glass
capillary was dipped into each sample, with the capillary held horizontally to ensure that the capillary was full of the sample. The
capillaries were placed on the capillary holder on the Nanotemper Prometheus. Technical triplicates of each sample were prepared,
and each experiment was conducted with biological triplicates of each protein. PR.ThermControl software was used to run the
experiment and analyse the data. A melting curve from 20 C – 95 C at 5 C/min was performed. The minimum of the first derivative
of the 330/350nm ratio was used to determine the Tm1/2.
Crystallization of apo DPAGT1 protein
Protein was concentrated to20 mg/ml, then diluted to 9–12 mg/ml using GFB without detergent. Initial crystals were grown at 4 C
with WT protein purified with DOPG using sitting drop (150 nl) crystallization set up in 96- well format using a Mosquito crystallization
robot (TTP Labtech) with protein:reservoir ratios of 2:1, 1:1 and 1:2. Crystals of DPAGT1 were initially obtained in MemGold2 HT-96
screen (Molecular Dimensions) condition G10. Reproducibility for this condition was poor, and protein purification was further opti-
mized. Adding cardiolipin instead of DOPG to purification buffers as well as using the Val264Gly mutant construct improved crystal
reproducibility. A new crystallization condition was obtained at 20 C which was optimized to 32%—38% (v/v) polyethylene
glycol (PEG) 300, 50 mM sodium chloride, 0-5 mM sodium tungstate, 0.1 M bicine, pH 9.0. Seeding was used to further improve
crystallization reproducibility.
Crystallization of the Val264Gly mutant DPAGT1 with UDP-GlcNAc and Tunicamycin
To obtain a co-structure of DPAGT1 with UDP-GlcNAc, Val264Gly DPAGT1 was incubated with 10 mM UDP-GlcNAc for 1 hour at
4 C before setting up crystallization with seeds at 20 C in reservoir solution containing 32.5%–38% (v/v) PEG 300, 50 mM NaCl,
0.1 M bicine, pH 9.0. To obtain a co-structure of DPAGT1 with tunicamycin, Val264Gly DPAGT1 harvested after SEC was supple-
mented with 0.1 mM tunicamycin and incubated for 1 hour at 4 C before concentrating. The concentrated protein was crystallized
at 4 C in sitting drop crystallization trials with reservoir solution containing 36% (v/v) PEG 200, 50 mM sodium chloride, 0.1 M bicine,
pH 8.5.
Data collection and structure determination for the DPAGT1 complexes
All data were collected at Diamond Light Source (beamlines I24, I04-1 and I04) to resolutions between 3.2-3.6 A˚ based on CC1/2=0.5
criteria. Data were processed, reduced and scaled using XDS (Kabsch, 2010) and AIMLESS (Evans, 2006) (Table S2). All crystals
belong to space group P6522 and contain a single DPAGT1monomer in the asymmetric unit with 70%solvent. Initial phase estimates
were obtained using molecular replacement (MR). Briefly, an initial search model was built automatically using the PHYRE2 web
server (Kelley et al., 2015) based on the coordinates of the bacterial homolog MraY (19% sequence identity; PDB: 4J72). However,
this simple homology model failed to produce any meaningful MR solutions when used in isolation in PHASER (McCoy et al., 2007).
The PHYRE model was then subjected to model pre-refinement using the procedures implemented in MR-ROSETTA in PHENIX
(Terwilliger et al., 2012) and the resultant five best-scoring output models were trimmed at their termini and in the TMH9/TMH10
cytoplasmic loop region and superposed for use as an ensemble search model in PHASER. A marginal but consistent solution
was obtained that exhibited sensible crystal packing in space group P6522 but both the initial maps and model refinement were
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model_already_placed=True option. The resultant MR-ROSETTA output model had an R/Rfree of 42/46 and the electron density
maps showed new features not present in the input coordinates that indicated that the structure had been successfully phased.
Using the MR-ROSETTA solution as a starting point, the remaining regions of the DPAGT1 structure could be built manually using
COOT (Emsley et al., 2010) using theWT 3.6 A˚ native data. However, the novel 52 amino acid cytoplasmic insertion domain between
TMH9 and TMH10 was poorly ordered and proved difficult to trace. This region was primarily traced using the electron density maps
for the UDP-GlcNAc complex as substrate binding results in partial stabilization of the TMH9/10 insertion domain. All electron density
maps were sharpened in COOT to aid model building using a B-factor of -100 A˚2. Sequence assignment was aided by using both
mercury labelling of cysteines (Figure S2A) and the sulphur anomalous signal from a dataset collected from UDP-GlcNAc complexes
crystals at awavelength of 1.7 A˚ (Figure S2B). Anomalous differencemaps, combinedwith anomalous substructure completion using
PHASER-EP, clearly revealed the location of 18 of the expected 22 sulphur positions and helped to confirm the sequence register
(Figure S2B). Additional experimental phasing information was provided by a Pr3+ derivative. The resultant model for the entire chain
was then refined against both the unbound Val264Gly (3.2 A˚), Val264Gly UDP-GlcNAc (3.1 A˚), Val264Gly tunicamycin (3.4 A˚) as well
as theWT unbound (3.6 A˚) data using BUSTER v2.10.2 / v2.10.3 and REFMAC (UDP-GlcNAc complex – final cycle only). All data were
mildly anisotropic but were used in BUSTER without truncation apart from the unbound Val264Gly dataset which was anisotropically
truncated with STARANISO using default cutoffs. Reference model restraints improved the refinement behavior for the 3.6 A˚ un-
bound WT structure (using the unbound Val264Gly model as the reference model). Ligand restraints were generated using the
GRADE webserver (http://grade.globalphasing.org) and a single TLS group encompassing the entire protein chain was used in
refinement. The presence of a single magnesium ion in the UDP-GlcNAc complex was verified using the anomalous signal from a
dataset collected at 1.82 A˚ from a crystal grown in the presence of MnCl2. A single peak (19s) was observed in an anomalous dif-
ference Fourier map calculated at 4 A˚ adjacent to UDP-GlcNAc pyrophosphate; the next highest peak corresponded to various
sulphur atoms (5s). A second putative Mn2+/Mg2+ site was identified between E94 and H270 on the luminal face (peak height
4.3s). Elongated lipid–like density on the TMH1/6/7/10 face of DPAGT1 was modelled as a dioleoylphosphoglycerol (DOPG) lipid.
This lipid feature was present in both the electron density maps of the WT structure (purified with DOPG added) and the various
Val264Gly mutant structures (purified with cardiolipin). The presence of DOPG in the purified protein samples used for crystallization
was detected bymass spectrometry (Figure S1I). Lipid-like density was also present in the concave putative Dol-P groove adjacent to
the EL4 luminal hairpin and has beenmodelled as unknown lipid/alkyl chains (UNL) in both the UDP-GlcNAc and TUN complexes. An
additional persistent feature in all structures was electron density at the mouth of the active site adjacent to Trp122 (TMH4) and
Leu293 (TMH9), presumably arising from a co-purified lipid that mimics the Dol-P substrate binding. However, the density was poorly
resolved and no attempt was made to interpret this feature in the final models. The commercial preparation of TUN used for co-crys-
tallization in this study is a natural product and contains a range of different aliphatic chain lengths (n=8-11). A chain length of n=9was
chosen for the modelled TUN as this appeared to most consistent with the observed electron density (Figure S2E).
The representative final model comprises the entire polypeptide chain between residues Leu7 and Gln400 apart from the flexible
EL2 loop connecting TMH2 and TMH3 and part of the poorly-ordered EL4 luminal hairpin (residue 152-161).
Native mass spectrometry
For native mass spectrometry analysis purified DPAGT1 protein was diluted to 10 mM protein concentration using 200 mM
ammonium acetate supplemented with 0.16% OGNG solution followed by buffer exchanged into 200 mM ammonium acetate,
0.16%OGNG using amicro biospin column (Micro Bio-Spin 6, Bio-Rad). Native MS experiments were conducted using a Q Exactive
instrument (Thermo Fisher, Germany) with modifications for high-mass transmission optimization. Typically, 2 ml of buffer exchanged
protein solution was electrosprayed from gold-plated borosilicate capillaries prepared in house. The instrument was operated under
following parameters: 1.2 kV capillary voltage, 100V S-lens, 250 C capillary temperature, 100 cone voltage. The activation voltage
in HCD cell was raised from 100-200 V until a nicely resolve charge state pattern was found. Pressure in the HCD cell was raised to
1.2e-9 mbar for efficient transmission of protein. The instrument was operated in positive ionmode and was calibrated using caesium
iodide solution.
For protein activity detection, 5 mMDPAGT1 protein was incubated separately with 50 mMdolichol-phosphate and UDP-GlcNAc or
together in presence of both substrates at 37 C for 21 min. Native MS buffer was used to spray the protein in presence of substrates
on a modified Q Exactive Plus instrument. For detection of phosphate groups the instrument was operated in negative mode and
minimal activation conditions were applied. The instrument was calibrated using cesium iodide. The experiments were repeated
three times using three different protein preparations.
Lipid analysis by tandem mass spectrometry
Lipidomics analysis was performed on DPAGT1 to identify co-purified lipid using typical reversed-phase liquid chromatography
coupled to tandem mass spectrometry method after modifications in liquid chromatography gradient. Protein was digested with
trypsin (1:50 units) for overnight at 37 C in a thermomixer (Eppendorf) under continuous shaking. The digest was dried in a SpeedVac
until complete dryness and re-dissolved in 68% solution A (ACN:H2O 60:40, 10 mM ammonium formate and 0.1% formic acid) and
32% solution B (IPA:ACN 90:10, 10mM ammonium formate and 0.1% formic acid). The tryptic digest mixture was loaded onto a pre-
equilibrated C18 column (Acclaim PepMap 100, C18, 75 mm3 15 cm; Thermo Scientific) at a flow rate of 300 nl min-1. The lipids were
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held at 80% for 10 min, then ramped to 99% over 6 min and held for 7 min. The nano-flow reversed-phase liquid chromatography
(Dionex UltiMate 3000 RSLC nano System, Thermo Scientific) was directly coupled to an LTQ-Orbitrap XL hybrid mass spectrometer
(Thermo Scientific) via a dynamic nanospray source. Typical MS conditions were spray voltage of 1.6 kV and capillary temperature of
275 C.
The LTQ-Orbitrap XL was set up in negative ion mode and in data-dependent acquisition mode to perform five MS/MS scans per
MS scan. Survey full-scan MS spectra were acquired in the Orbitrap (m/z 350–2,000) with a resolution of 60,000. The chromatogram
was manually analysed for presence of different masses followed by lipids identification by manually comparing their experimental
and theoretical fragmentation pattern.
Exon Trap Analysis
DPAGT1 exons 2, 3 and 4 and flanking intronic sequences or exons 6, 7 and 8 and flanking sequences were cloned into the pET01
vector (MoBiTec). c.478G>A and c.791T>G were respectively introduced by site-directed mutagenesis using Quikchange kit from
Stratagene and confirmed by Sanger sequencing. Control and mutant vector DNA were electroporated into the human rhabdomyo-
sarcoma cell line TE671 using the NEON electroporator (Invitrogen). Total RNA was purified 48 hr after transfection, reverse tran-
scribed into cDNA using Retroscript kit (Ambion). cDNA was amplified using primers specific to the vector exons. The amplicons
were run on agarose/TBE gels, visualized under UV/ethidium bromide and then gel purified and sequenced.
Mueller-Hinton Agar Plate
Muller-Hinton agar plate was prepared according to CLSI standards. OxoidMueller-Hinton Agar was prepared according to theman-
ufacture’s protocol. 25 ml of the warm agar solution was transferred to 90 mm x 16.2 mm plate via sterile pipette. The agar plate was
cooled at room temperature for 15 minutes before use or storage at 4 C up to two weeks.
Kirby-Bauer Disc Diffusion Test
Oxoid Blank Disc was impregnated with the desired test substance. A 0.5McFarland standard inoculumwas prepared by adding 3-5
single colonies to 10 mLMH broth in 15 mL-falcon tube and standardized to 0.5-McFarland standard. The inoculum was used within
10 minutes. A sterile cotton swab was dipped in the inoculum, gently pressed against the side of the tube to remove excess liquid,
and generously streaked onMH agar plate to fully cover the plate. The impregnated disc was carefully placed on the agar (important:
once the disc touches the agar, it should not be moved). The plate was incubated at 35 C for 20 hrs overnight. A digital calliper was
used to measure the zone diameter. The recorded zone diameter is an average of three zone diameters measured of one zone.
Micro-dilution culture to determine minimal inhibition and minimal bactericidal concentrations
In a sterile 96-well plate, serial dilutions were made with the test substance to final volume of 50 ml. Inoculum was then prepared in
Mueller-Hinton broth to 0.5 McFarland and diluted before adding 50 ml to the well to make 1x105 CFU/ml. The culture plate was
incubated at 35 C for 20-24 hrs. A positive growth control and sterility wells were also prepared along with the culture wells.
Absorbance at OD600 was taken using BMG Labtech SPECTROstar Omega spectrophotometer. MIC is determined by the lowest
concentration without growth. IC50 is determined from plotting a dose-response curve, see Data Analysis below. To determine
theMBC, using amulti-channel pipette, 1 ml of culture broth was taken from the same 96-well microdilution growth plate and carefully
inoculated on surface of MH agar plate. The plate is then incubated for additional 20 hrs. at 35 C. The MBC value is the lowest
concentration without observed growth on the agar.
Cell proliferation assay
In sterile 96-well plate, each well was seeded with 1x105 cells. The cells are then grown confluent overnight in 100 ml DMEM with
10% FBS. The medium is replenished with DMEM with 2% FBS and added vehicle control or test substance the next day. For test
substance in methanol, stock was added to 25 ml of DMEMwith 2% FBS or PBS and placed in the laminar flow hood to let the meth-
anol evaporate (about 1-3 hrs). Once the methanol has evaporated, DMEM with 2% FBS was added to final volume of 100 ml of
desired test concentration. A blank methanol control was also made to ensure that any cytotoxicity did not result from methanol
contamination. Cells are grown for additional 24 hrs. The cell viability was determined by using Promega CellTiter 96ª AQueous
One Solution Cell Proliferation Assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS) System following the manufacture protocol.
24 Hr Cell Cycle Test
The cell cycle tests were carried out in 96-well tissue culture plates. A T-75 tissue culture flask was first used to culture a stock of
HEK293 cells. Once the cells were approximately 90% confluent, the old medium was decanted and the cells were carefully washed
with PBS and resuspended in DMEM with 10% FBS. HEK293 cells are seeded into the 96-well plates (1x105 cells/well). Before
placing the culture in the incubator (37 C with 5% CO2), the plate was set aside for 10 minutes for the cells to settle to the bottom
of the plate. DMEMwith 2%FBS containing the test substance is prepared beforehand. Once the cells were confluent the next day or
when they were ready to be treated, the test compound in DMEM with 2% FBS was added and the cells were cultured for the
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Once the cell culture was ready for harvesting, the cells were then fixed with cold 70% ethanol after twowashes with PBS (w/ 0.1%
BSA). The cells were fixed overnight at 4 C.
Propidium Iodide (PI)/RNase Staining Solution from NEB was used for DNA staining
For test substances in methanol, the compound in a methanol containing stock solution was added to 50 ul of DMEM or PBS in a
round-well plate (8-well plate) and placed in the laminar hood for 1 – 2 hrs to remove the methanol by evaporation and then the
required amount of DMEM with 2% FBS was added to give the desired volume.
Time-course Cell Cycle Test
The time-course cell cycle test was carried out in 96-well tissue culture plate. Three sets of plates were prepared as described above
with samples prepared in triplicate. A 0 hr control cell culture was first collected before setting up the plates for treatment. Each set is
used for 24 hr, 48 hr or 72 hr time-point data collection. Due to nature of the experiment, the DMEM used contained 10% Heat-in-
activated FBS for the cells to have enough nutrients to the 72 hr cell cycle. Once the cell culture was ready for harvesting, the cells
were then fixed with cold 70% ethanol after two washes with PBS (w/v 0.1% BSA). The cells were fixed overnight at 4 C. Propidium
Iodide (PI)/RNase Staining Solution from NEB was used for DNA staining.
IgG1Fc N-Glycosylation Assay
The test can be carried out in 6- or 8-well tissue culture plate. The transfected HEK293T/pHLsec:IgG1Fc cell culture harboring
pHLsec:IgG1Fc plasmid with a His6-Tag IgG1Fc (Transfection protocol below) was grown for 2-3 days (37
C with 5% CO2). Then
the growth medium was collected and analyzed by SDS-PAGE and western blot analysis.
Transfection Protocol
Transfection reagents and medium were prepared fresh every time. A PEI (Polyethylimine) stock solution was first prepared (25 kDa,
linear -100 mg/mL). PEI was added in MilliQ water and HCl (aq) was then added drop-wise with just enough to help solubilize the PEI.
The PEI solution was filtered through 0.2 um membrane in laminar sterile hood. PEI solution was set aside. The DNA stock solution
was added to serum-free DMEMmedium at room temperature to make final DNA-DMEM concentration of 4 mg/mL. PEI solution was
then added to DMEM-DNA solution to make a final concentration of PEI of 4.6 mg/mL. The PEI-DNA transfection medium was gently
stirred at room temperature for 20minutes before use. For the transfection step, the DNA-PEI transfection was added first and placed
in the incubator (37 Cwith 5%CO2) for 10minutes and then DMEMwith 2% FBSwas added. The DNA-PEI medium and DMEMwith
2% FBS medium were added in 1:3 ratio.
Statistical Analysis
Data were analysed using Graph Pad PRISM 5.01 software. Dose-response curves were plotted from three independent data sets
with SEM error bars.
Minimum inhibitory concentrations testing against Mtb
MtbH37RvATCC27294wasgrown toOD650nmof 0.2 ineitherGlycerol-Alanine saltsmedium (GAST/Fe)or 7H9/ADC/Tw.GAST/Fecon-
sisted of per liter: 0.3 g Bacto Casitone (Difco), 4.0 g dibasic potassium phosphate, 2.0 g citric acid, 1.0 g L-alanine, 1.2 g magnesium
chloride hexahydrate, 0.6 g potassium sulfate, 0.05 g ferric ammonium citrate, 2.0 g ammonium chloride, 1.80 ml of 10N NaOH, and
10.0 ml of glycerol, 0.05% Tween 80 with pH adjusted to 6.6 before sterile filtration. 7H9/ADC/Tw consisted of Middlebrook 7H9 broth
base (Becton Dickinson) supplemented with 0.2% glycerol/0.5% BSA fraction V/ 0.2% glucose/ 0.08%NaCl/ 0.05% Tween 80. Cells
were diluted 1000-fold in this medium and an equal volume (50 ml/well) added to 96-well U-bottom plates (Nunclon, Thermo Scientific)
containing compounddiluted in the respective growthmedium (50 mL/well). Dilutions ranged from0.024 - 50 mg/mL, performed in tech-
nical duplicates over two biological repeats. The positive control was isoniazid (tested from0.024 - 50 mM) and negative control was the
solvent. Isoniazid MIC was 0.2 ± 0.1 mM. MIC was determined over 2-3 biological replicates, each time as a technical duplicate.
Generation of resistant mutants and whole genome sequencing
Mtb H37Rv ATCC27294 was grown to OD650nm of 0.5 in 7H9/ADC/Tw, harvested and resuspended at 10
10, 109 and 108 CFU/ml.
Aliquots (0.1 ml) were spread on solid medium consisting of Middlebrook 7H11 (Becton Dickinson) supplemented with OADC [final
concentration of 0.5% bovine serum albumin fraction V, 0.08% NaCl, 0.2% glucose, 0.2% glycerol, 0.06% oleic acid] containing
10X MIC concentration of TUN-8,8 or TUN-10,10. Colonies (1 for Tun-8,8 and 1 for TUN-10,10) that grew after 4-5 weeks of incu-
bation were picked, grown up in 7H9/ADC/Tw liquid medium and resistance confirmed by MIC determination as described above.
The observed frequency of resistance was 10-9 with 16-fold level of resistance recorded to the TUN-analogues. Genomic DNA was
purified by the CTABmethod (van Soolingen et al., 1991) and whole genome sequencing by Illumina MiSeq and assembly of paired-
end reads by SPAdes performed as previously described (Weingarten et al., 2018). A resistant mutant raised against TUN-10,10 had
a SNP at position 842361 (C to G) resulting in an Ala to Gly mutation in Rv0751c. A resistant mutant raised to TUN-8,8 had a T to A
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Macromolecular incorporation assay
Mtb H37Rv ATCC27294 was grown to OD650nm of 0.6 in 7H9/ADC/Tw was treated at 37
C under constant agitation with 20 mCi/mL
of D[-6-3H]-glucosamine (American Radiolabeled Chemicals, Inc. 40 Ci/mmol) for 2 h followed by addition of compound (TUN-8,8,
tunicamycin, meropenem/clavulanate or DMSO as vehicle control) at 1X or 10XMIC concentrations. MIC concentrations for controls
were as follows: D-cycloserine 29 mM, meropenem 2 mM with clavulanate used at a fixed concentration of 100 mM, tunicamycin
1.1 mM.After 24 h and 48 h incubation, 100 ml of culture was precipitated with 100 ml of 20%TCA in a round bottom 96well polystyrene
(Nunclon) plate. Precipitates were aspirated with a cell harvester (Perkin Elmer) and transferred to 96 well filtermat. The precipitates
on the GF/C filtermats (Perkin Elmer) were washed twice with 200 ml 10% TCA, and subsequently three times with 200 ml of 70%
ethanol. The filtermat was removed, dried overnight and then soaked with 5 ml of Betaplate scintillation cocktail (Perkin Elmer)
followed by mounting in a filtermat holder. It was counted by Microbeta2 microplate scintillation counter (Perkin Elmer).
GFP release assay
Mtb-GFP (M. tuberculosisH37Rv (ATCC 27294) transformedwith the plasmid pMSP12::GFP [Addgene plasmid # 30167]) was grown
to an OD650nm of 0.2 in 7H9/ADC/Tw and split into 30 ml aliquots in 250 ml roller bottles. Drug or vehicle control was added to each
aliquot and the culture returned to 37 C in a rolling bottle incubator. At indicated time points, 1 ml culture was removed, cells har-
vested at 13,000 rpm for 10 minutes and 100 ml supernatant transferred in triplicates to black 96-well plates (Thermo Fisher Sientific,
USA) and fluorescence recorded in a FLUOstar Optima plate reader (BMG Labtech) at 485 nm excitation/ 520 nm emission
wavelengths.
BODIPY-Vancomycin staining of nascent peptidoglycan
Mtb H37Rv ATCC27294 was grown to OD650nm of 0.2 in 7H9/ADC/Tw and 5 ml volumes treated for up to 48 h with tunicamycin,
TUN-8,8, meropenem/clavulanate or DMSO after which BODIPY-Vancomycin was added to a final concentration of 1 mg/ml. After
18 h of incubation, 3 ml of the suspension was harvested by centrifugation and washed twice in 1 ml PBS. The cell pellet was
resuspended in 100 ml of fixative (2.5% glutaraldehyde in 100mM sodium cacodylate buffer) and 10 ml spread on a poly-L- lysine
coatedmicroscope slide onto which was added 50 ml of mountingmedium (ProLongGold Antifade reagent; Thermo Fisher Scientific,
USA) and a coverslip. The slides were visualized by confocal fluorescence microscopy (Excitation 485 nm, Emission 520 nm) after
overnight incubation at 4 C.
Microsomal stability assay protocol
NADPH-regenerating system was freshly prepared by combining (a) 37.2 mg glucose-6-phosphate into 1 ml of 100 mM potassium
phosphate buffer, (b) 39.8 mg NADP into 1 ml of 100 mM potassium phosphate buffer, (c) 11.5 U glucose-6-phosphate dehydroge-
nase into 1 mL of 100 mM potassium phosphate buffer and (d) 26.8 mg MgCl2.6H2O into 1 ml of water. 271 ml phosphate buffer
(100 mM, pH 7.4) and 18 ml of NADPH-regenerating system were added to each tube, which were kept on ice. Pooled mouse/human
liver microsomeswere removed from the -80 C freezer and thawed. 8 ml of liver microsomes (protein content >20mg/ml) were added
to each tube. The tubes were removed from ice and placed in a 37 C heating block. 3 ml of test compound (0.5mM stock) was added
(final concentration 5 mM). Control incubation was included for each compound where phosphate buffer was added instead of
NADPH-regenerating system (minus NADPH). Verapamil was used as control in the assay. The reaction was quenched at selected
time-points by the addition of 150 ml methanol containing 5 mM internal standard. The samples were removed from the heating block
and centrifuged at 14,000 g at 4 C for 10 min. The supernatants were analyzed on LC/MS under single ionization mode (SIM) and
scan mode.
Testing of tunicamycin analogue efficacy against Mtb growing in infected macrophages
J774A.1 mouse macrophage cells were grown in J774 growth medium consisting of DMEM GlutaMAX (Gibco) supplemented with
10% fetal bovine serum, 20mMHEPES + 0.5mM sodium pyruvate, seeded in sterile tissue culture treated 24-well plates (Corning) at
2.5x105 cells/well and allowed to attach for 24 h in J774 growthmedium.MtbH37Rv ATCCwas grown toOD650nm of 0.2 in 7H9/ADC/
Tw, harvested, resuspended in J774 growth medium, filtered through a 5 mm filter to ensure a single cell suspension and diluted to
2.5x107 cells/ml. Cells were infected with 0.1 mLMtb cell suspension at a multiplicity of infection (MOI) of 10:1 and allowed for 24 h.
After infection, the medium was aspirated and the monolayer of cells washed twice with Dulbecco’s PBS and subsequently fed with
1ml of J774 growthmedium containing the compounds at the indicated concentrations in triplicate wells for each drug concentration
and time point. Rifampicin was used as positive control andmethanol and DMSO used for the negative controls. After 3 and 7 days of
treatment, cells were lysed by 0.1% SDS, appropriate dilutions made in 7H9/ADC/Tw and plated in duplicate on solid medium
consisting of Middlebrook 7H11 (Becton Dickinson) supplemented with OADC [final concentration of 0. 5% bovine serum albumin
fraction V, 0.08%NaCl, 0.2%glucose, 0.2%glycerol, 0.06%oleic acid]. Colony counts were enumerated after 4weeks of incubation.
Mouse pharmacokinetics
Test compoundwas dosed to sixteen female C57BL/6mice by intraperitoneal injection in a volume of 0.6ml. To reconstitute TUN-8,8
for intraperitoneal injections, compound (1 mg) was dissolved in 0.1 ml ethanol and subsequently diluted with 0.9 ml 1% Tween 80 in
Dulbecco’s PBS. Themixture waswarmed to 37 C, vortexed and sonicated followed by sterile filtration through a 0.2 mmfilter. Bloode8 Cell 175, 1045–1058.e1–e9, November 1, 2018
samples were taken from the tail vein of the mice at pre-determined time intervals post-dose, and serum collected after 4 h on
ice. 30 ml serum samples were prepared with 30 ml internal standard and 20 ml of water or spiked standard along with 240 ml
of ACN/MeOH mix (3:1) to precipitate proteins. Samples were centrifuged 13 krpm for 5 minutes and 2 ml injected into LC-MS/MS
system. Calibration standard was prepared 1 mg of TUN-8,8 to 1 ml DMSO and successively diluted by a factor of 3. TUN-9,9 IS
solution was prepared to 200 mg/ml in DMSO.
LC-MS/MSwas performed on an Agilent 1290 Infinity HPLC coupled to an Agilent 6460C triple quadrupolemass selective detector
with electrospray ionization in positive mode. TUN-8,8 and TUN-9,9 (as an internal standard) were detected using their M+H precur-
sors ions with 514.1 and 528.2 Da/z product ions produced in a collision cell using collision energy 12 V. Capillary voltage was 3000 V
and ESI used jet stream technology with sheath voltage 2000 V. The column was an Agilent C18 Poroshell 120 2.7 mm with dimen-
sions 2.1 x 50mmat 40 C.Mobile phasewaswater (A) and acetonitrile (B) eachwith 0.1% (v/v) formic acid.With flow rate 0.8ml/min,
a gradient of 25% B progressed to 95% B over 4 minutes, washed and re-equilibrated. Water for LC-MS/MS was purified by a
Barnstead Diamond system to 18.2 MU-cm resistivity. Acetonitrile (ACN) and Methanol were HPLC grade from Fisher (Fairlawn
NJ, USA) and formic acid was supplied from EMD Millipore Corp (Darmstadt, Germany). DMSO was ACS grade manufactured by
Amresco LLC in Solon Ohio USA.
Mouse infection
Female C57Bl/6micewere aerosol-infectedwith 100-200 colony forming units ofMtbH37Rvwith implantation dose determined after
24 hours by plating of lung homogenates on Middlebrook 7H11/OADC agar. Nine days after infection, five mice were euthanized
and lung and spleens harvested for bacterial burden enumeration by plating of organ homogenates on Middlebrook 7H11/OADC
agar. The remaining mice were treated in groups of 10 as follows: (1) daily intraperitoneal injections of 0.2 ml 10% ethanol/0.9%
Tween 80/Dulbecco’s PBS; (2) daily intraperitoneal injections of 10 mg/kg TUN-8,8 in 0.2 ml 10% ethanol/0.9% Tween 80/
Dulbecco’s PBS; (3) oral gavage of 10 mg/kg Rifampicin in in 0.1ml water. Mice were treated daily for 2 weeks after which mice
were euthanized and organ homogenates in 7H9/ADC/Tw plated on Middlebrook 7H11/OADC agar for colony enumeration.
Preparation of figures
Figures were prepared using either PyMOL (Schrodinger, 2010) or UCSF-Chimera (Pettersen et al., 2004). Electrostatic surface
potentials (Figure 2B) were calculated using the APBS plugin within PyMOL and the PDB2PQR server (Dolinsky et al., 2004).
Hydrogens and missing sidechain atoms were added automatically to the refined X-ray structure using ICM-Pro (Molsoft LLC) prior
to electrostatic surface calculations. All electrostatic surface potentials were visualized in UCSF-Chimera and colored between -10
(red) and +10 (blue) kT/e-.
QUANTIFICATION AND STATISTICAL ANALYSIS
All values are the mean ± standard deviation. GraphPad Prism v7.02 was used to plot Michaelis-Menten curves using the least
squares fitting method and calculate the vmax and Km values.
DATA AND SOFTWARE AVAILABILITY
The crystal structures presented in this paper have been deposited in the PDB with accession numbers: 5LEV, 5O5E, 6FM9
and 6FWZ.
Additional Resources
DPAGT1 target enabling package: http://www.thesgc.org/tep/DPAGT1Cell 175, 1045–1058.e1–e9, November 1, 2018 e9
Supplemental Figures
Figure S1. Biochemical and Biophysical Characterization of DPAGT1, Related to Figure 1
(A) Cartoon of DPAGT1 showing the reaction it performs.
(B) Cartoon of MraY showing the reaction it performs.
(C) The identity of the substrate Dol-P and the product, GlcNAc-PP-Dol, was confirmed by mass spectrometry. Top spectrum is DPAGT1 incubated with Dol-P
only, bottom spectra are DPAGT1 incubated with both Dol-P and UDP-GlcNAc.
(D) Comparison of the catalytic activity of DPAGT1 WT and Val264Gly mutant protein (n=9).
(E) The thermostability of DPAGT1WT (black) and Val264Gly (grey) mutant proteins tested using label free differential scanning fluorimetry. The effects of addition
of the substrates Dol-P and UDP-GlcNAc, and the inhibitor tunicamycin on thermostability of DPAGT1 were also tested (n=9).
(F) Product inhibition was observed with the product analogue GlcNAc-PP-Und, but not with UMP (n=9).
(G) DPAGT1 is completely inhibited by a 1:1 ratio of tunicamycin:protein (n=9).
(H) Lipidomics analysis of OGNG purified DPAGT1 showed the presence of co-purified phospholipid in addition to the supplemented cardiolipin associated with
the protein.
(I) The presence of phosphatidylglycerol is confirmed by tandem mass spectrum of the most intense phospholipid in the lipidomics analysis.
For all panels, data presented are means ± SD.
Figure S2. Electron Density Maps, Heavy Atom Phasing and Dimer Interface Analysis for the Structure of Dimeric WT and Gly264Val Mutant
of DPAGT1 Solved at Resolutions up to 3.2 A˚, Related to Figure 2
(A) Hg bound sites from a soaked crystal. 6 A˚ anomalous difference Fouriermap calculated from a dataset collected from a crystal soakedwith EMTS is contoured
at 5s (purple) and 3s (magenta mesh) and overlaid on the final model. Cysteine positions are highlighted by cyan sticks. Labelling of five of the nine ordered
cysteines (Cys42, Cys72, Cys106 (weak), Cys217 and Cys299) is observed under the soaking conditions used.
(B) S-SAD peaks. The PHASER-EP log-likelihoodmap after anomalousmodel completion with sulphur atoms is shown overlaid on a cartoon representation of the
final UDP-GlcNAc complex. The positions of cysteine (cyan sticks) and methionine (blue sticks) residues are highlighted. Themap is contoured at 4.5s (magenta)
and 2.5s (pink mesh). Peaks are observed for 16 sulphur atoms (out of a total of 18 possible ordered sulphurs) and the pyrophosphate of the UDP-GlcNAc is also
resolved.
(C and D) Two views of final 2Fo-Fc AUTOBUSTER electron density map around the active site in the UDP-GlcNAc complex. Themap has been sharpened using a
B-factor of -100 A˚2 in COOT and is contoured at 1.5s and overlaid on the final model. UDP-GlcNAc is shown in ball-and-stick form (carbon-magenta, oxygen-red,
phosphorus-orange, nitrogen-blue).
(E) Omit Fo-Fc electron density map for tunicamycin. The omit difference density is contoured at 2.5s (green mesh) and a sharpened omit Fo-Fc density map
(B=-100 A˚2) is contoured at 2s and overlaid on the final tunicamycin coordinates. Density for tunicamycin’s alkyl tail is not as well resolved as the TUN core.
(F and G) Comparison of dimer organization in DPAGT1 (F) and unbound MraY (PDB: 5JNQ) (G) in crystals, indicating that DPAGT1 and MraY are both
‘‘head-to’head’’ dimers in their respective crystals, but the dimer interfaces are unrelated.
(legend continued on next page)
(H) Size exclusion chromatography from a DPAGT1 purification with activity data per fraction per unit of protein shown as box plot, indicating that there is no
difference in the activity of DPAGT1 across the peak (n=6).
(I) Native mass spectrometry confirms that DPAGT1 is a mixture of monomers and dimers.
(J) Electron density at the dimer interface between adjacent Cys106 residues in TMH3, with the sharpened (-100 A˚2) 2FoFc density shown in blue (contoured
at 1.0sigma) and ‘‘omit’’ density from a refinement where the sidechain of Cys106 was omitted (green mesh, contoured at 6.0sigma).
Figure S3. The c.478G>A; Gly160Ser and c.791T>G; Val264Gly Mutations Are Associated with Exon Splicing Errors, Resulting in the Loss of
Exons 2 and 3 from the Transcript Harbouring c.478G>A; Gly160Ser and the Loss of Exons 6 and 7 from the Transcript Harbouring c.791T>G;
Val264Gly, Related to Figure 4
(A) Schematic of pET01 exon trap vector with DPAGT1 exons 2-4 inserted showing the location within the genomic sequence of c.478G>A; Gly160Ser.
(B) Sequencing data and schematic diagrams showing aberrant splicing that results from genomic sequence harbouring the c.478G>A; Gly160Ser variant.
RT-PCR on RNA produced in TE671 muscle cell line following transfection with the ‘‘exon trap’’ vector gave wild type RNA sequence, but also some transcripts
that excluded exons 2 and 3. When the genomic sequence contained the c.478G>A; Gly160Ser variant was transfected only RNA missing exons 2 and 3 was
detected.
(C) Schematic of pET01 exon trap vector with DPAGT1 exons 6-8 inserted showing the location within the genomic sequence of the c.791T>G; Val264Gly variant.
(D) Sequencing data and schematic diagrams showing sequences obtained following RT-PCR on TE671 cells transfected with the ‘‘exon trap’’ vector containing
human genomic DNA that is either wild type or has the c.791T>G; Val264Gly variant. Wild type sequence generated RNA harbouring only exons 6, 7 and 8,
as shown. The c.791T>G; Val264Gly variant generated some RNA transcripts containing exons 6, 7 and 8 (as for wild type) but for the majority of transcripts
exons 6 and 7 were excluded and only exon 8 was present.
Figure S4. Kirby-Bauer Disc Diffusion Tests andDose Response Curves Used forMIC,MBC, and IC50 Determination for Tunicamycin and the
TUN-X,X Analogues against Several Bacterial Strains, Related to Figure 5
(A–E) Kirby-Bauer disc diffusion tests for the TUN analogues against bacterial strains (A)B. subtilis EC 1524, (B)M. luteus, (C)B. cereus ATCC 11778, (D) S. aureus
ATCC 29219 and (E) P. aeruginosa ATCC 27853. Discs impregnated with 5 mg, unless otherwise indicated, of the compound were laid onto plates with lawns
of bacteria. The compounds are labelled: TC: commercial tunicamycin, TS: tunicamycin from S. chartreusis, 2: (2) N-acetyl tunicamine, Ac: TUN-Ac,Ac, Boc:
TUN-Boc,Boc, 7: TUN-7,7, 8: TUN-8,8, 9: TUN-9,9, 10: TUN-10,10, 11: TUN-11,11, 12: TUN-12,12, Cit: TUN-Cit,Cit, Amp: ampicillin, Gen: gentamycin.
(F–J) Dose response curves for tunicamycin and the analogues with (F) B. subtilis EC1524. (G) B. cereus ATCC11778. (H) S. aureus ATCC29219. (I) P. aeruginosa
ATCC27853 and (J) E. coli ATCC25922. These dose-response curves were generated by Prism 6.0 software by plotting percent growth (normalized OD600
values) vs. logarithmic scale of the concentrations. The data shown aremean ±SEMerrors of three independent experiments. See Table S3 for theMIC,MBC and
IC50 values.
Figure S5. On-Target Effects Demonstrated for the TUN-8,8 Analogue, Related to Figure 5
(A) Glucosamine incorporation within 48 h was reduced with 10x TUN-8,8. Positive controls were tunicamycin, meropenem/clavulanate (MCA) and D-cycloserine
(DCS). All compounds tested at 1- and 10-fold MIC concentrations (n=2).
(B) GFP release assay. Mtb expressing GFP was treated with 1- and 10-fold MIC concentrations of TUN-8,8 or tunicamycin. Lysis was monitored by mea-
surement of fluorescence in cell-free supernatants daily over a week of exposure as a measure of release of cytosolic protein (GFP) (n=2).
(C) Confocal microscopy of BODIPY-vancomycin used to track synthesis of PG, showing abnormal PG formation with tunicamycin and TUN-8,8 treated Mtb,
both differing from the effects of pentapeptide labelling by the BODIPY-vancomycin caused by meropenem/clavulanate treatment.
Data presented in (A) and (B) are means ± SD.
Figure S6. Effect of Tunicamycin and Analogues on HEK293 Cells, Related to Figure 6
(A) Cell cycle analysis at 24 hours.
(B–D) Cell morphology with (B) tunicamycin, (C) TUN-8,8 and (D) TUN-9,9.
(E–G) Effects of (E) tunicamycin, (F)TUN-8,8 and (G)TUN-9,9 on glycosylation of amodel protein – IgG1Fc-His6. Black arrow indicates glycosylated protein, white
arrow indicates unglycosylated protein.
